Trademark Overview
On Tuesday, January 9, 2024, a trademark application was filed for RILABNACEPT with the United States Patent and Trademark Office. The USPTO has given the RILABNACEPT trademark a serial number of 98348983. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, September 10, 2024. This trademark is owned by Hangzhou Gene-based Biopharmaceutical Co., Ltd.. The RILABNACEPT trademark is filed in the Pharmaceutical Products category with the following description:
Anti-inflammatory and antipyretic preparations; Anti-inflammatory preparations; Chemical reagents for medical purposes; Injectable pharmaceuticals for treatment of anaphylactic reactions; Pharmaceutical antitussive-cold preparations; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disor...
